AbbVie gets FDA approval for Hepatitis C combination therapy

AbbVie gets FDA approval for Hepatitis C combination therapy Daklinza plus sofosbuvir resulted in 90% SVR12 in treatment-naive and 86% in treatment-experienced chronic HCV genotype 3 patients. Most people infected with HCV have no symptoms of the disease until liver … Continue reading

Merck Gets Breakthrough Designation for Hepatitis C Drugs

Merck Gets Breakthrough Designation for Hepatitis C Drugs In 2013, the FDA had granted grazoprevir and elbasvir breakthrough status for their use on patients with hepatitis C genotype 1. The new breakthrough designations are for patients infected with chronic HCV … Continue reading